NASDAQ:SGYP

Synergy Pharmaceuticals (SGYP) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.01
$0.03
52-Week Range
N/A
Volume
N/A
Average Volume
6.08 million shs
Market Capitalization
$7.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SGYP stock logo

About Synergy Pharmaceuticals Stock (NASDAQ:SGYP)

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

SGYP Stock News Headlines

Jose Solorio
Better than Bitcoin? The Biotech Stock with 46,751% Potential
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Synergy Pharmaceuticals Inc Unit (SGYPU)
Different resistors
Mains cables
Energy changes in braking
Better than Bitcoin? The Biotech Stock with 46,751% Potential
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Jiangxi Synergy Pharmaceutical Co Ltd (300636)
OKYO Pharma LTD: OKYO Pharma Limited: Directorate Change
See More Headlines
Receive SGYP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synergy Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2018
Today
4/26/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SGYP
CUSIP
87163930
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-224,330,000.00
Net Margins
-332.11%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$16.82 million
Book Value
($0.02) per share

Miscellaneous

Free Float
N/A
Market Cap
$7.44 million
Optionable
Optionable
Beta
4.94
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Troy Hamilton Pharm.D. (Age 47)
    CEO & Director
  • Mr. Gary G. Gemignani (Age 54)
    Exec. VP & CFO
  • Gem Gokmen Hopkins
    VP of Investor Relations and Corp. Communications
  • Ms. Pamela Cebulski
    Sr. VP of Marketing
  • Ms. Marianne Jackson
    Sr. VP of Sales & Market Access

SGYP Stock Analysis - Frequently Asked Questions

How were Synergy Pharmaceuticals' earnings last quarter?

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) released its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.01. The biopharmaceutical company had revenue of $11.11 million for the quarter, compared to analysts' expectations of $15.65 million.

What other stocks do shareholders of Synergy Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Synergy Pharmaceuticals investors own include Novavax (NVAX), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Inovio Pharmaceuticals (INO), ACADIA Pharmaceuticals (ACAD), Cara Therapeutics (CARA), OPKO Health (OPK), Gilead Sciences (GILD), Exelixis (EXEL) and

This page (NASDAQ:SGYP) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners